Analyst Viewpoint
Rise in prevalence of rare chronic diseases is the primary contributor to the plasma fractionation market growth. Innovations in biotechnology ensure that identification of rare genetic illnesses is more accessible compared to previous decades.
Plasma protein derived medicines and therapies are used in the treatment of rare chronic diseases. This is fostering plasma fractionation industry growth.
Surge in demand for plasma proteins is also bolstering the plasma fractionation industry size. Governments and private sector alike are putting in consistent efforts in collecting plasma, as immune deficiencies and autoimmune disorders are becoming common.
Large numbers of plasma collection centers are opening globally to cater to the rising demand for plasma proteins. Prominent players in the global plasma fractionation market are investing substantially in plasma fractionation for rare blood disorders to make quality healthcare solutions accessible to a wider population.
Plasma fractionation is the primary process of large-scale protein purification. The process entails separation of several components of blood plasma, including vital proteins and other molecules such as immunoglobulins and albumin.
Blood plasma-derived products are used in a variety of therapeutic products to treat conditions such as autoimmune diseases, hemophilia, and rare deficiencies.
Plasma fractioning allows the production of a wide range of purified plasma products that are derived from a single source of plasma. It plays a vital role in the treatment of several medical conditions.
Recent plasma fractionation market trends indicate a shift toward premium product quality and safety. Additionally, advancements in blood fractionation and research in targeted medicine are gaining traction.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
Surge in geriatric population across the globe, environmental conditions, and preexisting genetic disposition are leading to a rise in cases of rare chronic diseases.
Advancements in medical science have made genetic testing more accessible. This has led to a record number of diagnosis and identification of rare conditions compared to previous decades.
Some examples of rare chronic diseases include hemophilia, hereditary angioedema, and immunodeficiency disorders. Plasma component isolation offers a potential solution for rare medical illnesses by sourcing therapeutic offerings from a single source of plasma.
As per analysis by Global Genes, more than 400 million people across the globe suffer from one out of 10,000 known rare genetic disorders. Among individuals diagnosed with a rare illness, 50% are children. The report also suggests that it takes nearly five years for an accurate diagnosis.
Increase in global old age population means that a large share of the population is on a trajectory to suffer from conditions such as liver problems, neurological issues, and immune deficiencies.
Plasma protein-derived therapy methods such as cell therapy and regenerative medicine are used in the treatment of these diseases and disorders. This is creating lucrative plasma fractionation market opportunities for players operating in the sector.
As per the Plasma Protein Therapeutics Association (PPTA), 8.4 million liters of plasma required for the manufacture of plasma-derived therapies was collected in the European Union in 2021. It was utilized to introduce relevant plasma-derived therapies.
Around 740 plasma collection centers exist in the U.S., according to the Federal Drug Agency. In Europe, the European Blood Alliance aims to promote plasma donation and currently nearly 111 plasma collection centers exist in the region.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
North America held the dominant plasma fractionation market share in 2022. Presence of reliable and established healthcare facilities, rise in awareness about availability of novel care solutions, and growth in R&D in new treatment methods are augmenting the market dynamics of the region.
According to a report by Rare Genomics, nearly 30 million people are affected by a rare genetic disease in the U.S., accounting for every 10th person in the country.
As per the latest plasma fractionation industry analysis, the industry in Europe is projected to grow at a steady pace from 2023 to 2031. Surge in investments in personalized medicine and treatment of genetic disorders along with supportive policies and guidelines implemented by governments of several countries in the region are propelling the plasma fractionation market statistics in Europe.
The European Commission states that more than 30 million people residing in the European Union suffer from some type of genetic condition. About 6,000 rare genetic diseases are registered and documented in the region.
Prominent manufacturers in the worldwide plasma fractionation market are investing significantly in the development of plasma product extraction and blood plasma separation processes to cater to the increase in demand for plasma proteins that are utilized in novel treatment of rare diseases.
CSL Limited, Takeda Pharmaceutical Company, Sanquin, Biotest AG, GRIFOLS, Baxter International Inc., Kedrion, Octapharma AG, and Taibang Biological Group Co., Ltd are key companies operating in the global landscape.
The plasma fractionation market report highlights parameters such as business strategies, product portfolio, company overview, financial overview, and business segments of the leading companies.
| Attribute | Detail |
|---|---|
| Market Value in 2022 (Base Year) | US$ 24.1 Bn |
| Market Forecast Value in 2031 | US$ 42.6 Bn |
| Growth Rate (CAGR) | 6.7% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon Request |
| Pricing | Available upon Request |
It was valued at US$ 24.1 Bn in 2022
It is projected to grow at a CAGR of 6.7% from 2023 to 2031
Increase in prevalence of rare chronic diseases and rise in demand for plasma proteins
North America dominated the global landscape in 2022
CSL Limited, Takeda Pharmaceutical Company, Sanquin, Biotest AG, GRIFOLS, Baxter International Inc., Kedrion, Octapharma AG, and Taibang Biological Group Co., Ltd
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Plasma Fractionation Market
4. Market Overview
4.1. Introduction
4.1.1. Technology, Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Plasma Fractionation Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Technology, /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Plasma Fractionation Market Analysis and Forecast, by Product Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product Type, 2017–2031
6.3.1. Immunoglobulin
6.3.1.1. Intravenous Immunoglobulin
6.3.1.2. Subcutaneous Immunoglobulin
6.3.2. Coagulation Factor Concentrates
6.3.2.1. Factor VIII
6.3.2.2. Factor IX
6.3.2.3. Factor XIII
6.3.2.4. Prothrombin Complex Concentrates
6.3.2.5. Von Willebrand Factor (VWF)
6.3.2.6. Fibrinogen Concentrates
6.3.3. Albumin
6.3.4. Protease Inhibitors
6.3.5. Other Plasma Products
6.4. Market Attractiveness Analysis, by Product Type,
7. Plasma Fractionation Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Neurology
7.3.2. Immunology
7.3.3. Hematology
7.3.4. Critical Care
7.3.5. Pulmonology
7.3.6. Others
7.4. Market Attractiveness Analysis, by Application
8. Plasma Fractionation Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals and Clinics
8.3.2. Clinical Research Laboratories
8.3.3. Academic Institutes
8.4. Market Attractiveness Analysis, by Application
9. Plasma Fractionation Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Plasma Fractionation Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Product Type, 2017–2031
10.3.1. Immunoglobulin
10.3.1.1. Intravenous Immunoglobulin
10.3.1.2. Subcutaneous Immunoglobulin
10.3.2. Coagulation Factor Concentrates
10.3.2.1. Factor VIII
10.3.2.2. Factor IX
10.3.2.3. Factor XIII
10.3.2.4. Prothrombin Complex Concentrates
10.3.2.5. Von Willebrand Factor (VWF)
10.3.2.6. Fibrinogen Concentrates
10.3.3. Albumin
10.3.4. Protease Inhibitors
10.3.5. Other Plasma Products
10.4. Market Value Forecast, by Application, 2017–2031
10.4.1. Neurology
10.4.2. Immunology
10.4.3. Hematology
10.4.4. Critical Care
10.4.5. Pulmonology
10.4.6. Others
10.5. Market Value Forecast, by End-user, 2017–2031
10.5.1. Hospitals and Clinics
10.5.2. Clinical Research Laboratories
10.5.3. Academic Institutes
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Product Type,
10.7.2. By Application
10.7.3. By End-user
10.7.4. By Country
11. Europe Plasma Fractionation Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Product Type, 2017–2031
11.3.1. Immunoglobulin
11.3.1.1. Intravenous Immunoglobulin
11.3.1.2. Subcutaneous Immunoglobulin
11.3.2. Coagulation Factor Concentrates
11.3.2.1. Factor VIII
11.3.2.2. Factor IX
11.3.2.3. Factor XIII
11.3.2.4. Prothrombin Complex Concentrates
11.3.2.5. Von Willebrand Factor (VWF)
11.3.2.6. Fibrinogen Concentrates
11.3.3. Albumin
11.3.4. Protease Inhibitors
11.3.5. Other Plasma Products
11.4. Market Value Forecast, by Application, 2017–2031
11.4.1. Neurology
11.4.2. Immunology
11.4.3. Hematology
11.4.4. Critical Care
11.4.5. Pulmonology
11.4.6. Others
11.5. Market Value Forecast, by End-user, 2017–2031
11.5.1. Hospitals and Clinics
11.5.2. Clinical Research Laboratories
11.5.3. Academic Institutes
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Product Type
11.7.2. By Application
11.7.3. By End-user
11.7.4. By Country/Sub-region
12. Asia Pacific Plasma Fractionation Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Product Type, 2017–2031
12.3.1. Immunoglobulin
12.3.1.1. Intravenous Immunoglobulin
12.3.1.2. Subcutaneous Immunoglobulin
12.3.2. Coagulation Factor Concentrates
12.3.2.1. Factor VIII
12.3.2.2. Factor IX
12.3.2.3. Factor XIII
12.3.2.4. Prothrombin Complex Concentrates
12.3.2.5. Von Willebrand Factor (VWF)
12.3.2.6. Fibrinogen Concentrates
12.3.3. Albumin
12.3.4. Protease Inhibitors
12.3.5. Other Plasma Products
12.4. Market Value Forecast, by Application, 2017–2031
12.4.1. Neurology
12.4.2. Immunology
12.4.3. Hematology
12.4.4. Critical Care
12.4.5. Pulmonology
12.4.6. Others
12.5. Market Value Forecast, by End-user, 2017–2031
12.5.1. Hospitals and Clinics
12.5.2. Clinical Research Laboratories
12.5.3. Academic Institutes
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Product Type,
12.7.2. By Application
12.7.3. By End-user
12.7.4. By Country/Sub-region
13. Latin America Plasma Fractionation Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Product Type, 2017–2031
13.3.1. Immunoglobulin
13.3.1.1. Intravenous Immunoglobulin
13.3.1.2. Subcutaneous Immunoglobulin
13.3.2. Coagulation Factor Concentrates
13.3.2.1. Factor VIII
13.3.2.2. Factor IX
13.3.2.3. Factor XIII
13.3.2.4. Prothrombin Complex Concentrates
13.3.2.5. Von Willebrand Factor (VWF)
13.3.2.6. Fibrinogen Concentrates
13.3.3. Albumin
13.3.4. Protease Inhibitors
13.3.5. Other Plasma Products
13.4. Market Value Forecast, by Application, 2017–2031
13.4.1. Neurology
13.4.2. Immunology
13.4.3. Hematology
13.4.4. Critical Care
13.4.5. Pulmonology
13.4.6. Others
13.5. Market Value Forecast, by End-user, 2017–2031
13.5.1. Hospitals and Clinics
13.5.2. Clinical Research Laboratories
13.5.3. Academic Institutes
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Product Type,
13.7.2. By Application
13.7.3. By End-user
13.7.4. By Country/Sub-region
14. Middle East & Africa Plasma Fractionation Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Product Type, 2017–2031
14.3.1. Immunoglobulin
14.3.1.1. Intravenous Immunoglobulin
14.3.1.2. Subcutaneous Immunoglobulin
14.3.2. Coagulation Factor Concentrates
14.3.2.1. Factor VIII
14.3.2.2. Factor IX
14.3.2.3. Factor XIII
14.3.2.4. Prothrombin Complex Concentrates
14.3.2.5. Von Willebrand Factor (VWF)
14.3.2.6. Fibrinogen Concentrates
14.3.3. Albumin
14.3.4. Protease Inhibitors
14.3.5. Other Plasma Products
14.4. Market Value Forecast, by Application, 2017–2031
14.4.1. Neurology
14.4.2. Immunology
14.4.3. Hematology
14.4.4. Critical Care
14.4.5. Pulmonology
14.4.6. Others
14.5. Market Value Forecast, by End-user, 2017–2031
14.5.1. Hospitals and Clinics
14.5.2. Clinical Research Laboratories
14.5.3. Academic Institutes
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Product Type,
14.7.2. By Application
14.7.3. By End-user
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. CSL Limited
15.3.1.1. Company Overview
15.3.1.2. Technology, Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Takeda Pharmaceutical Company
15.3.2.1. Company Overview
15.3.2.2. Technology, Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Sanquin
15.3.3.1. Company Overview
15.3.3.2. Technology, Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Biotest AG
15.3.4.1. Company Overview
15.3.4.2. Technology, Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. GRIFOLS
15.3.5.1. Company Overview
15.3.5.2. Technology, Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Baxter International Inc.
15.3.6.1. Company Overview
15.3.6.2. Technology, Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Kedrion
15.3.7.1. Company Overview
15.3.7.2. Technology, Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Octapharma AG
15.3.8.1. Company Overview
15.3.8.2. Technology, Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Taibang Biological Group Co., Ltd
15.3.9.1. Company Overview
15.3.9.2. Technology, Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
List of Tables
Table 01: Plasma Fractionation Market Size (US$ Mn) Forecast, by Product Type, 2017–2031
Table 02: Plasma Fractionation Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 03: Plasma Fractionation Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 04: Plasma Fractionation Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Plasma Fractionation Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Plasma Fractionation Market Size (US$ Mn) Forecast, by Product Type, 2017–2031
Table 07: North America Plasma Fractionation Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 08: North America Plasma Fractionation Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 09: Europe Plasma Fractionation Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Plasma Fractionation Market Size (US$ Mn) Forecast, by Product Type, 2017–2031
Table 11: Europe Plasma Fractionation Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 12: Europe Plasma Fractionation Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 13: Asia Pacific Plasma Fractionation Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Plasma Fractionation Market Size (US$ Mn) Forecast, by Product Type, 2017–2031
Table 15: Asia Pacific Plasma Fractionation Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 16: Asia Pacific Plasma Fractionation Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 17: Latin America Plasma Fractionation Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Plasma Fractionation Market Size (US$ Mn) Forecast, by Product Type, 2017–2031
Table 19: Latin America Plasma Fractionation Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 20: Latin America Plasma Fractionation Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 21: Middle East & Africa Plasma Fractionation Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Plasma Fractionation Market Size (US$ Mn) Forecast, by Product Type, 2017–2031
Table 23: Middle East & Africa Plasma Fractionation Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 24: Middle East & Africa Plasma Fractionation Market Size (US$ Mn) Forecast, by End-user, 2017–2031
List of Figures
Figure 01: Plasma Fractionation Market Size (US$ Mn) and Distribution (%), by Region, 2017–2031
Figure 02: Plasma Fractionation Market Revenue (US$ Mn), by Product Type, 2022
Figure 03: Plasma Fractionation Market Value Share, by Product Type, 2022
Figure 04: Plasma Fractionation Market Revenue (US$ Mn), by Application, 2022
Figure 05: Plasma Fractionation Market Value Share, by Application, 2022
Figure 06: Plasma Fractionation Market Revenue (US$ Mn), by End-user, 2022
Figure 07: Plasma Fractionation Market Value Share, by End-user, 2022
Figure 08: Plasma Fractionation Market Value Share, by Region, 2022
Figure 09: Plasma Fractionation Market Value (US$ Mn) Forecast, 2017–2031
Figure 10: Plasma Fractionation Market Value Share Analysis, by Product Type, 2017–2031
Figure 11: Plasma Fractionation Market Attractiveness Analysis, by Product Type, 2023–2031
Figure 12: Plasma Fractionation Market Value Share Analysis, by Application, 2017–2031
Figure 13: Plasma Fractionation Market Attractiveness Analysis, by Application, 2023–2031
Figure 14: Plasma Fractionation Market Value Share Analysis, by End-user, 2017–2031
Figure 15: Plasma Fractionation Market Attractiveness Analysis, by Product Type, 2023–2031
Figure 16: Plasma Fractionation Market Value Share Analysis, by Region, 2017–2031
Figure 17: Plasma Fractionation Market Attractiveness Analysis, by Region, 2017–2031
Figure 18: North America Plasma Fractionation Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 19: North America Plasma Fractionation Market Attractiveness Analysis, by Country, 2017–2031
Figure 20: North America Plasma Fractionation Market Value Share Analysis, by Country, 2017–2031
Figure 21: North America Plasma Fractionation Market Value Share Analysis, by Product Type, 2017–2031
Figure 22: North America Plasma Fractionation Market Value Share Analysis, by Application, 2017–2031
Figure 23: North America Plasma Fractionation Market Value Share Analysis, by End-user, 2017–2031
Figure 24: North America Plasma Fractionation Market Attractiveness Analysis, by Product Type, 2023–2031
Figure 25: North America Plasma Fractionation Market Attractiveness Analysis, by Application, 2023–2031
Figure 26:North America Plasma Fractionation Market Attractiveness Analysis, by Product Type, 2023–2031
Figure 27: Europe Plasma Fractionation Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 28: Europe Plasma Fractionation Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 29: Europe Plasma Fractionation Market Value Share Analysis, by Country/Sub-region, 2017–2031
Figure 30: Europe Plasma Fractionation Market Value Share Analysis, by Product Type, 2017–2031
Figure 31: Europe Plasma Fractionation Market Value Share Analysis, by Application, 2017–2031
Figure 32: Europe Plasma Fractionation Market Value Share Analysis, by End-user, 2017–2031
Figure 33: Europe Plasma Fractionation Market Attractiveness Analysis, by Product Type, 2023–2031
Figure 34: Europe Plasma Fractionation Market Attractiveness Analysis, by Application, 2023–2031
Figure 35: Europe Plasma Fractionation Market Attractiveness Analysis, by Product Type, 2023–2031
Figure 36: Asia Pacific Plasma Fractionation Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 37: Asia Pacific Plasma Fractionation Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 38: Asia Pacific Plasma Fractionation Market Value Share Analysis, by Country/Sub-region, 2017–2031
Figure 39: Asia Pacific Plasma Fractionation Market Value Share Analysis, by Product Type, 2017–2031
Figure 40: Asia Pacific Plasma Fractionation Market Value Share Analysis, by Application, 2017–2031
Figure 41: Asia Pacific Plasma Fractionation Market Value Share Analysis, by End-user, 2017–2031
Figure 42: Asia Pacific Plasma Fractionation Market Attractiveness Analysis, by Product Type, 2023–2031
Figure 43: Asia Pacific Plasma Fractionation Market Attractiveness Analysis, by Application, 2023–2031
Figure 44: Asia Pacific Plasma Fractionation Market Attractiveness Analysis, by Product Type, 2023–2031
Figure 45: Latin America Plasma Fractionation Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 46: Latin America Plasma Fractionation Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 47: Latin America Plasma Fractionation Market Value Share Analysis, by Country/Sub-region, 2017–2031
Figure 48: Latin America Plasma Fractionation Market Value Share Analysis, by Product Type, 2017–2031
Figure 49: Latin America Plasma Fractionation Market Value Share Analysis, by Application, 2017–2031
Figure 50: Latin America Plasma Fractionation Market Value Share Analysis, by End-user, 2017–2031
Figure 51: Latin America Plasma Fractionation Market Attractiveness Analysis, by Product Type, 2023–2031
Figure 52: Latin America Plasma Fractionation Market Attractiveness Analysis, by Application, 2023–2031
Figure 53: Latin America Plasma Fractionation Market Attractiveness Analysis, by Product Type, 2023–2031
Figure 54: Middle East & Africa Plasma Fractionation Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 55: Middle East & Africa Plasma Fractionation Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 56: Middle East & Africa Plasma Fractionation Market Value Share Analysis, by Country/Sub-region, 2017–2031
Figure 57: Middle East & Africa Plasma Fractionation Market Value Share Analysis, by Product Type, 2017–2031
Figure 58: Middle East & Africa Plasma Fractionation Market Value Share Analysis, by Application, 2017–2031
Figure 59: Middle East & Africa Plasma Fractionation Market Value Share Analysis, by End-user, 2017–2031
Figure 60: Middle East & Africa Plasma Fractionation Market Attractiveness Analysis, by Product Type, 2023–2031
Figure 61: Middle East & Africa Plasma Fractionation Market Attractiveness Analysis, by Application, 2023–2031
Figure 62: Middle East & Africa Plasma Fractionation Market Attractiveness Analysis, by Product Type, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Plasma Fractionation Market
